Ensysce net loss widens to $2.6 million in Q2 FY26; R&D expenses rise to $2.5 million

Reuters2026/08/13 20:26

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Ensysce Biosciences posted a Q2 net loss of $2.6 million, widening from a $1.7 million loss a year earlier.
Cash and cash equivalents fell to $676,704 at June 30 from $4.3 million at Dec. 31, 2025.
R&D expense rose to $2.5 million from $1.9 million, driven by higher external costs tied to PF614 clinical activity.
Federal grant funding slipped to $1.2 million from $1.4 million on timing of MPAR grant-eligible research.
Completed Cy Biopharma acquisition, adding orphan-designated CRPS candidate CY200; financings provided about $31 million net cash, extending runway into late 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ensysce Biosciences Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 202608131615ACCESSWRNAPR_____1207099) on August 13, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Ensysce net loss widens to $2.6 million in Q2 FY26; R&D expenses rise to $2.5 million

You may also like

Crypto prices